Hypera (HYPE3) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
19 Jan, 2026Working capital optimization strategy and financial outlook
Working capital optimization aims to increase cash generation by BRL 2.5 billion by 2028 and BRL 7.5 billion over ten years through reduced accounts receivable and inventory levels, aligning with industry standards.
The process will be gradual over six quarters, targeting a reduction in accounts receivable from 116 to 60 days by end-2025, with no expected impact on sell-out growth.
Operational improvements include AI-driven demand planning, reduced delivery lead times, and enhanced distribution center efficiency.
Maintains focus on sell-out growth, with Q3 and October 2024 increases of approximately 11% and 13%, alongside continued portfolio diversification and R&D investments.
Preliminary Q3 2024 results: net revenue around R$1.9 billion, EBITDA of R$561 million, and net income of R$370 million.
Short- and medium-term impacts
Net revenue, EBITDA, and net profit will be temporarily reduced during the adjustment period (2024-2025), but main investments and sell-out growth will be preserved.
Margin reductions are expected to be temporary, with operational efficiency gains anticipated from 2026 onward.
The strategy is aligned with client needs, releasing distribution center space and improving logistics, with no major impact expected on client working capital.
Sell-out growth remains strong, reaching 9% year-to-date, and a new share buyback program for up to 30 million shares was announced.
Discontinued 2024 financial guidance, which previously projected net revenue of R$8.6 billion, adjusted EBITDA of R$3.0 billion, and net income of R$1.85 billion.
Share repurchase program details
Approved a new share repurchase program for up to 30 million common shares (7.487% of free float), replacing the previous program, with a maximum term of 18 months from October 18, 2024, to April 18, 2026.
Repurchased 1.75 million shares under the previous program, with 3.25 million remaining unconsumed; the new program supersedes the old one.
Repurchased shares may be held in treasury, cancelled, sold, or used for stock-based compensation, with no impact on capital stock.
May use derivatives for hedging obligations related to stock-based compensation; all transactions will occur on B3 at market prices.
No impact expected on control or administrative structure; intermediaries include Bradesco, Credit Suisse, Ágora, Itaú, and XP Investimentos.
Latest events from Hypera
- Net revenue up 86.7% YoY, EBITDA at R$586.5M, net debt down 17.8% after capital increase.HYPE3
Q1 202614 Jul 2026 - EBITDA margin held at 33.7% as working capital optimization improved cash metrics.HYPE3
Q2 202514 Jul 2026 - Net revenue fell 40.8%, but record cash flow and continued investments show resilience.HYPE3
Q1 202514 Jul 2026 - Strong revenue and margin growth, record cash flow, and improved leverage in 3Q25.HYPE3
Q3 202514 Jul 2026 - Sell-out up 11% and free cash flow up 23.2%, despite lower revenue and profit.HYPE3
Q3 202414 Jul 2026 - Sell-out up 6.3%, record cash flow, net debt down, and innovation pipeline drives outlook.HYPE3
Q2 202414 Jul 2026 - Net revenue fell 6% as working capital optimization drove record cash flow and strong sell-out.HYPE3
Q4 202414 Jul 2026 - Net revenue grew 3.4% to R$7.7B, with record cash flow and strong retail outperformance.HYPE3
Q4 20256 Jul 2026 - Market leader with strong growth, innovation, and broad branded portfolio in Brazilian pharma.HYPE3
Corporate presentation7 Apr 2026